Evidence map›Paper›PMID 27569602›Full record

ArticlePharmacology, biochemistry, and behavior

Rapid and sustained antidepressant properties of an NMDA antagonist/monoamine reuptake inhibitor identified via transporter-based virtual screening.

Jeffery N Talbot, Laura M Geffert, Jessica E Jorvig, Ruben I Goldstein, Cienna L Nielsen, Nicholas E Wolters, Mary Ellen Amos, Caitlin A Munro, Elizabeth Dallman, Maddalena Mereu and 7 more

Open access · greenAbstract read
In one paragraph

Article in Pharmacology, biochemistry, and behavior. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. (Proceedings of the National Academy of Sciences of the United States of America · 2019
    Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 7 institutions in 1 country.

Jeffery N TalbotResearch Center on Substance Abuse and Depression, College of Pharmacy, Roseman University of Health Sciences, 11 Sunset Way, Henderson, NV 89014, USA. Electronic address: jtalbot@roseman.edu.
Laura M GeffertDivision of Pharmaceutical Sciences, Mylan School of Pharmacy, Duquesne University, 600 Forbes Avenue, Pittsburgh, PA 15282, USA.
Jessica E JorvigResearch Center on Substance Abuse and Depression, College of Pharmacy, Roseman University of Health Sciences, 11 Sunset Way, Henderson, NV 89014, USA.
Ruben I GoldsteinResearch Center on Substance Abuse and Depression, College of Pharmacy, Roseman University of Health Sciences, 11 Sunset Way, Henderson, NV 89014, USA.
Cienna L NielsenDepartment of Basic Sciences, Touro University Nevada, 874 American Pacific Dr., Henderson, NV 89014, USA.
Nicholas E WoltersRaabe College of Pharmacy, Ohio Northern University, 525 S. Main St., Ada, OH 45810, USA.
Mary Ellen AmosRaabe College of Pharmacy, Ohio Northern University, 525 S. Main St., Ada, OH 45810, USA.
Caitlin A MunroRaabe College of Pharmacy, Ohio Northern University, 525 S. Main St., Ada, OH 45810, USA.
Elizabeth DallmanRaabe College of Pharmacy, Ohio Northern University, 525 S. Main St., Ada, OH 45810, USA.
Maddalena MereuPsychobiology Section, National Institute on Drug Abuse, Intramural Research Program, NIH, Baltimore, MD 21224, USA.
Gianluigi TandaPsychobiology Section, National Institute on Drug Abuse, Intramural Research Program, NIH, Baltimore, MD 21224, USA.
Jonathan L KatzPsychobiology Section, National Institute on Drug Abuse, Intramural Research Program, NIH, Baltimore, MD 21224, USA.
Martín IndartePhusis Therapeutics, Inc., 3210 Merryfield Row, San Diego, CA 92121, USA.
Jeffry D MaduraDepartments of Chemistry and Biochemistry, Center for Computational Sciences, Duquesne University, 600 Forbes Avenue, Pittsburgh, PA 15282, USA.
Hailey ChoiDivision of Pharmaceutical Sciences, Mylan School of Pharmacy, Duquesne University, 600 Forbes Avenue, Pittsburgh, PA 15282, USA.
Rehana K LeakDivision of Pharmaceutical Sciences, Mylan School of Pharmacy, Duquesne University, 600 Forbes Avenue, Pittsburgh, PA 15282, USA.
Christopher K SurrattDivision of Pharmaceutical Sciences, Mylan School of Pharmacy, Duquesne University, 600 Forbes Avenue, Pittsburgh, PA 15282, USA. Electronic address: surratt@duq.edu.
Ohio Northern University · USDuquesne University · USNational Institute on Drug Abuse · USRoseman University of Health Sciences · USMylan (United States) · USPhusis Therapeutics (United States) · USTouro University Nevada · US

Funding

Investigation On The Behavior And Related Neuro-Electrochemistry Of Potential Medications For The Treatment Of Substance Use Disorders.ZIADA000611 · NIDA · NATIONAL INSTITUTE ON DRUG ABUSE · PI TANDA, GIANLUIGI · 2016 to 2025
$16.0M
Basic Dopamine Transporter Mechanisms Of CocaineZIADA000103 · NIDA · NATIONAL INSTITUTE ON DRUG ABUSE · PI KATZ, JONATHAN L · 2009 to 2016
$4.6M
CRCNS: Computational and experimental study of dopamine and serotonin transporterR01DA027806 · NIDA · DUQUESNE UNIVERSITY · PI MADURA, JEFFRY D. · 2009 to 2013
$1.5M
Dopamine Transporter Structure and FunctionR01DA026530 · NIDA · DUQUESNE UNIVERSITY · PI SURRATT, CHRISTOPHER K · 2009 to 2010
$627k
Intramural NIH HHS Z99 DA999999NIDA NIH HHS R01 DA026530NIDA NIH HHS R01 DA027806NIDA NIH HHS Y01 DA005007
6 · The paper itself

Abstract

Rational design of lead compounds targeting monoamine transporters (MATs) is critical to developing novel therapeutics to treat psychiatric disorders including depression and substance abuse. A 3-D dopamine transporter (DAT) computer model was used to virtually screen a commercially available small molecule library for high DAT affinity drug-like compounds. One hit, coded "MI-4", inhibited human dopamine, norepinephrine, and serotonin transporters in vitro. In vivo administration in mice induced robust, dose-dependent antidepressant-like behaviors in learned helplessness models (tail suspension and forced swim tests). Moreover, chronic administration (21day, 10mg/kg, bid) reduced drinking latencies comparable to fluoxetine (10mg/kg, bid) in the novelty-induced hypophagia test, which requires chronic treatment to produce antidepressant-like effects. MI-4 (10mg/kg, bid) produced rapid (three-day) antidepressant-like effects in the social avoidance test following 10days of social defeat stress. Unlike ketamine, chronic administration of MI-4 increased social interaction scores while improving resiliency to the mood-altering effects of stress to over 70%. Importantly, MI-4 exhibited minimal abuse liability in behavioral and neurological models (conditioned place preference and dopamine in vivo microdialysis). MI-4 was found to be Ro-25-6981, an ifenprodil analog and reputed NMDA antagonist. The data suggest that Ro-25-6981, previously known for rapid-acting glutamatergic antidepressant actions, may also functionally inhibit monoamine reuptake and produces sustained antidepressant effects in vivo. This demonstrates, as proof of principle, the viability of combining these mechanisms to produce rapid and sustained antidepressant-like effects. Overall, these findings suggest MAT computational model-based virtual screening is a viable method for identifying antidepressant lead compounds of unique scaffold.

Indexed as

AnimalsAntidepressive AgentsComputer SimulationDopamine Uptake InhibitorsDose-Response Relationship, DrugMiceMice, Inbred C57BLNeuroprotective AgentsN-MethylaspartatePhenolsPiperidinesSelective Serotonin Reuptake InhibitorsAntidepressive AgentsDopamine Uptake InhibitorsNeuroprotective AgentsN-MethylaspartatePhenolsPiperidinesRo 25-6981Selective Serotonin Reuptake InhibitorsAntidepressantKetamineMonoamine transporterRo-25-6981Serotonin selective reuptake inhibitorVirtual screen

Identifiers

PMID27569602
PMCPMC9575003
OpenAlexW2510927228

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.